Yield10 Bioscience delisted from Nasdaq as of May 16

In Massachusetts, Yield10 Bioscience announced the company received a final delisting notice from Nasdaq. The delisting is a result of failure to regain compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain stockholder’s equity of at least $2,500,000. Suspension of trading in the company’s common stock on the Nasdaq exchange became effective at the open of trading on May 16, 2024.

Following the Nasdaq delisting, shares of the company’s common stock will continue to trade publicly. Effective May 16, 2024, the company’s common stock is eligible for quotation and trading on the “over the counter” market operated by the OTC Markets Group Inc. The company’s trading symbol will remain YTEN. For stock price quotes or additional information on the OTC Market, please visit www.otcmarkets.com. The Company plans to apply for trading on the OTC-QB market.

The company does not expect the transition to the OTC Market to affect business operations. The company remains focused on executing its business plan and will explore any and all strategic opportunities, both internally and externally, that have the ability to advance the development of Camelina, as well as grow shareholder value.